Efficacy of Panobinostat for the Treatment of Multiple Myeloma

Panobinostat represents a potent oral nonselective pan-histone deacetylase inhibitor (HDAC) with activity in myeloma patients. It has been approved by the FDA and EMA in combination with bortezomib and dexamethasone for the treatment of multiple myeloma, in patients who have received at least two pr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Oncol
Autores principales: Eleutherakis-Papaiakovou, Evangelos, Kanellias, Nikolaos, Kastritis, Efstathios, Gavriatopoulou, Maria, Terpos, Evangelos, Dimopoulos, Meletios Athanasios
Formato: Artigo
Lenguaje:Inglês
Publicado: Hindawi 2020
Materias:
Review Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7201625/
https://ncbi.nlm.nih.gov/pubmed/32411240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/7131802
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares